Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05856747 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Two Bioanalytical Assays for Tebipenem
A Phase 1 study, sponsored by Spero Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05856747 is a Phase 1 study that has completed, run by Spero Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT05856747, a Phase 1 study, has completed, sponsored by Spero Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary purpose of the study is to compare the concentrations of tebipenem (TBP), the active moiety of tebipenem pivoxil hydrobromide (TBP-PI-HBr), as determined by two bioanalytical assays, a whole blood assay and a plasma assay, following a single oral dose of TBP-PI-HBr 600 milligram (mg) tablets in healthy adult participants.
Interventions
- DRUG TBP-PI-HBr
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05856747
The ClinicalTrials.gov registry entry for NCT05856747 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spero Therapeutics, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TBP-PI-HBr is the first listed.
NCT05856747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05856747 about?
NCT05856747 is a clinical study titled "A Study to Compare Two Bioanalytical Assays for Tebipenem". The primary purpose of the study is to compare the concentrations of tebipenem (TBP), the active moiety of tebipenem pivoxil hydrobromide (TBP-PI-HBr), as determined by two bioanalytical assays, a whole blood assay and a plasma assay, following a single oral dose of TBP-PI-HBr 600 milligram (mg) tab...
What is the current status of trial NCT05856747?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-05-04. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT05856747?
The interventions under investigation include: TBP-PI-HBr (DRUG).
Who is sponsoring clinical trial NCT05856747?
This trial is sponsored by Spero Therapeutics, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.